GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (OTCPK:MEDIF) » Definitions » EV-to-EBITDA

MediPharm Labs (MediPharm Labs) EV-to-EBITDA : -1.63 (As of Jun. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MediPharm Labs's enterprise value is $12.84 Mil. MediPharm Labs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.87 Mil. Therefore, MediPharm Labs's EV-to-EBITDA for today is -1.63.

The historical rank and industry rank for MediPharm Labs's EV-to-EBITDA or its related term are showing as below:

MEDIF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.51   Med: -0.69   Max: 2463.26
Current: -1.63

During the past 7 years, the highest EV-to-EBITDA of MediPharm Labs was 2463.26. The lowest was -21.51. And the median was -0.69.

MEDIF's EV-to-EBITDA is ranked worse than
100% of 710 companies
in the Drug Manufacturers industry
Industry Median: 14.09 vs MEDIF: -1.63

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-24), MediPharm Labs's stock price is $0.055795. MediPharm Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.029. Therefore, MediPharm Labs's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


MediPharm Labs EV-to-EBITDA Historical Data

The historical data trend for MediPharm Labs's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs EV-to-EBITDA Chart

MediPharm Labs Annual Data
Trend Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial 49.32 -1.52 -0.43 0.14 -0.99

MediPharm Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.60 -1.50 -0.99 -1.65

Competitive Comparison of MediPharm Labs's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediPharm Labs's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MediPharm Labs's EV-to-EBITDA falls into.



MediPharm Labs EV-to-EBITDA Calculation

MediPharm Labs's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=12.842/-7.872
=-1.63

MediPharm Labs's current Enterprise Value is $12.84 Mil.
MediPharm Labs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediPharm Labs  (OTCPK:MEDIF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MediPharm Labs's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.055795/-0.029
=At Loss

MediPharm Labs's share price for today is $0.055795.
MediPharm Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.029.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


MediPharm Labs EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MediPharm Labs (MediPharm Labs) Business Description

Traded in Other Exchanges
Address
151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis extracts and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.